References
- Quasim M M. Techniques and results of half body irradiation (HBI) in metastatic carcinomas and myelomas. J Clin Oncol 1979; 5: 65–68
- Mill W B, Griffith R. The role of radiation therapy in the management of plasma cell tumors. Cancer 1980; 45: 647–652
- Mendenhall C M, Thar T L, Million R R. Solitary plasmacytoma of bone and soft tissue. J Radiat Oncol 1980; 6: 1497–1501
- Harwood A R, Knowling M A, Bergsagel D E. Radiotherapy of extramedullary plasmacytoma of the head and neck. Clin Radiol 1981; 32: 31–36
- Jaffe J P, Bosch A, Raich P C. Sequential hemi-body radiotherapy in advanced multiple myeloma. Cancer 1979; 43: 124–128
- Douer D, Champlin R E, Ho W G, et al. High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer. Am J Med 1981; 71: 973–978
- Hiramoto R N, McGhee J R, Hurst D C, et al. Study of single radial hemolysis in gel system I. Factors affecting the model. Immunochemistry 1971; 8: 355–365
- McGhee J R, Hurst D C, Hamlin N M, et al. Study of the single radial hemolysis in gel system II. Application of the model to mouse 19S hemolytic antibody. Immunochemistry 1971; 8: 367–373
- Ghanta V K, Hiramoto R N. Quantitation of total body tumor cells (MOPC 104E). I. Subcutaneous tumor model. J Natl Cancer Inst 1974; 52: 1199–1202
- Lynch R G, Rohrer J W, Odermatt B, et al. Immunoregulation of murine myeloma cell growth and differentiation: A monoclonal model of B-cell differentiation. Immunol Rev 1979; 48: 45–80
- Salmon S E, McIntyre O R, Ogawa M. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest 1970; 49: 1114–1121
- Salmon S E, Smith B A. IgE myeloma: Total body tumor cell number and synthesis of IgE and DNA. Blood 1971; 37: 696–705
- Bergsagel D E. Assessment of the response of mouse and human myeloma to chemotherapy and radiotherapy. Br Med J 1971; 2: 705–717
- Fitzpatrick P J, Rider W D. Half body radiotherapy. Int J Radiat Oncol 1976; 1: 197–207
- Lubet A, Carlson D E. Therapy of the murine plasmacytoma MOPC 104E: Role of the immune response. J Natl Cancer Inst 1978; 61: 897–903
- Selby P J, Millar J L, Phelps M Y. The combination of melphalan with prednisolone. Cancer Chemother Pharmacol 1981; 6: 169–173
- Byfield J E, Calabro-Jones P M. Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents. Nature 1981; 294: 281–283
- Ghanta V K, Hiramoto R N, Davis D W, et al. Maintenance of MOPC 104E myeloma in plateau phase. Cancer Res 1980; 40: 2372–2376
- Ghanta V K, Shrestha K, Durant J R, et al. Tumor proliferation and chemotherapy in immunosuppressed mice. Cancer Res 1983; 43: 1097–1100
- Miura T, Hayashida I, Ghanta V K, et al. Regulation and/or regression of MOPC 104E induced in vivo is not due to cytotoxic T-lymphocytes. Fed Proc 1983; 1197
- Osserman E, DiRe L, DiRe J, et al. Identical twin marrow transplantation in multiple myeloma. Acta Haemat 1982; 68: 215–223